Chronic Myeloid Leukemia Clinical Trials in Houston, Texas

9 studies are recruiting for chronic myeloid leukemia in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

   To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06817720 on ClinicalTrials.gov

2. Study of Olverembatinib (HQP1351) in Patients With CML-CP

   Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ascentage Investigative Site #1501, Houston, Texas

   Locations

   163 in total

   Run by

   Ascentage Pharma Group Inc.

   See if you can join NCT06423911 on ClinicalTrials.gov

3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

4. Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

   The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07269470 on ClinicalTrials.gov

5. Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

   To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06236724 on ClinicalTrials.gov

6. A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

   The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   45 in total

   Run by

   Enliven Therapeutics

   See if you can join NCT05304377 on ClinicalTrials.gov

7. A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

   Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be admin…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   11 in total

   Run by

   Crossbow Therapeutics, Inc.

   See if you can join NCT06994676 on ClinicalTrials.gov

8. A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

   The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML). The study has two parts: Part 1…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   54 in total

   Run by

   Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

   See if you can join NCT06163430 on ClinicalTrials.gov

9. Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

   A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   9 in total

   Run by

   Ascentage Pharma Group Inc.

   See if you can join NCT04260022 on ClinicalTrials.gov